MedTrace Logo

Methylprednisolone Injections Treating Birch Pollen Induced Allergic Rhinitis.

NCT04622917 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2024-03-15

No results posted yet for this study

Summary

This study evaluates the effect of intramuscular injected methylprednisolone treating birch pollen induced rhinitis compared to placebo.

Conditions

  • Rhinitis, Allergic, Seasonal
  • Hay Fever
  • Pollen Allergy
  • Allergic Rhinitis

Interventions

DRUG

MethylPREDNISolone 40 Mg/mL Injectable Suspension

intramuscular injection

DRUG

NaCl 9 MG/ML Injectable Solution

Intramuscular injection

Sponsors & Collaborators

Principal Investigators

  • Lars Olaf Cardell, Professor · Karolinska Institutet

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-04-10
Primary Completion
2022-06-20
Completion
2023-05-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04622917 on ClinicalTrials.gov